Nutrient  ||| S:0 E:9 ||| JJ
intake  ||| S:9 E:16 ||| NN
during  ||| S:16 E:23 ||| IN
an  ||| S:23 E:26 ||| DT
elite  ||| S:26 E:32 ||| JJ
level  ||| S:32 E:38 ||| NN
three-day  ||| S:38 E:48 ||| JJ
event  ||| S:48 E:54 ||| NN
competition  ||| S:54 E:66 ||| NN
is  ||| S:66 E:69 ||| VBZ
correlated  ||| S:69 E:80 ||| VBN
to  ||| S:80 E:83 ||| TO
inflammatory  ||| S:83 E:96 ||| JJ
markers  ||| S:96 E:104 ||| NN
and  ||| S:104 E:108 ||| CC
antioxidant  ||| S:108 E:120 ||| FW
status  ||| S:120 E:127 ||| FW
Dietary  ||| S:127 E:135 ||| FW
intake  ||| S:135 E:142 ||| FW
and  ||| S:142 E:146 ||| CC
feeding  ||| S:146 E:154 ||| VBG
management  ||| S:154 E:165 ||| NN
practices  ||| S:165 E:175 ||| NNS
could  ||| S:175 E:181 ||| MD
affect  ||| S:181 E:188 ||| VB
the  ||| S:188 E:192 ||| DT
degree  ||| S:192 E:199 ||| NN
of  ||| S:199 E:202 ||| IN
physiological  ||| S:202 E:216 ||| JJ
stress  ||| S:216 E:223 ||| NN
and  ||| S:223 E:227 ||| CC
subsequent  ||| S:227 E:238 ||| JJ
performance  ||| S:238 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
high  ||| S:253 E:258 ||| JJ
level  ||| S:258 E:264 ||| NN
3-day  ||| S:264 E:270 ||| CD
event  ||| S:270 E:276 ||| NN
horses ||| S:276 E:282 ||| NNS
.  ||| S:282 E:284 ||| .
To  ||| S:284 E:287 ||| TO
assess  ||| S:287 E:294 ||| VB
whether  ||| S:294 E:302 ||| IN
a  ||| S:302 E:304 ||| DT
relationship  ||| S:304 E:317 ||| NN
exists  ||| S:317 E:324 ||| VBZ
between  ||| S:324 E:332 ||| IN
dietary  ||| S:332 E:340 ||| JJ
intake  ||| S:340 E:347 ||| NN
levels  ||| S:347 E:354 ||| NNS
of  ||| S:354 E:357 ||| IN
selected  ||| S:357 E:366 ||| JJ
nutrients  ||| S:366 E:376 ||| NN
and  ||| S:376 E:380 ||| CC
the  ||| S:380 E:384 ||| DT
inflammatory  ||| S:384 E:397 ||| JJ
and  ||| S:397 E:401 ||| CC
antioxidant  ||| S:401 E:413 ||| JJ
status  ||| S:413 E:420 ||| NN
in  ||| S:420 E:423 ||| IN
horses  ||| S:423 E:430 ||| NNS
competing  ||| S:430 E:440 ||| VBG
in  ||| S:440 E:443 ||| IN
a  ||| S:443 E:445 ||| DT
high  ||| S:445 E:450 ||| JJ
level  ||| S:450 E:456 ||| NN
3-day  ||| S:456 E:462 ||| CD
event ||| S:462 E:467 ||| NN
.  ||| S:467 E:469 ||| .
Riders  ||| S:469 E:476 ||| NNS
competing  ||| S:476 E:486 ||| VBG
in  ||| S:486 E:489 ||| IN
a  ||| S:489 E:491 ||| DT
CCI2* ||| S:491 E:496 ||| CD
/ ||| S:496 E:497 ||| CD
CCI3*  ||| S:497 E:503 ||| CD
3-day  ||| S:503 E:509 ||| CD
event  ||| S:509 E:515 ||| NN
( ||| S:515 E:516 ||| -LRB-
n  ||| S:516 E:518 ||| CD
=  ||| S:518 E:520 ||| SYM
35 ||| S:520 E:522 ||| CD
)  ||| S:522 E:524 ||| -RRB-
answered  ||| S:524 E:533 ||| VBD
a  ||| S:533 E:535 ||| DT
nutritional  ||| S:535 E:547 ||| JJ
management  ||| S:547 E:558 ||| NN
survey  ||| S:558 E:565 ||| NN
conducted  ||| S:565 E:575 ||| VBN
by  ||| S:575 E:578 ||| IN
the  ||| S:578 E:582 ||| DT
investigators  ||| S:582 E:596 ||| NNS
at  ||| S:596 E:599 ||| IN
the  ||| S:599 E:603 ||| DT
competition ||| S:603 E:614 ||| NN
.  ||| S:614 E:616 ||| .
Actual  ||| S:616 E:623 ||| JJ
and  ||| S:623 E:627 ||| CC
recommended  ||| S:627 E:639 ||| VBD
intakes  ||| S:639 E:647 ||| VBN
of  ||| S:647 E:650 ||| IN
vitamin  ||| S:650 E:658 ||| JJ
E ||| S:658 E:659 ||| NN
,  ||| S:659 E:661 ||| ,
potassium  ||| S:661 E:671 ||| NNS
( ||| S:671 E:672 ||| -LRB-
K ||| S:672 E:673 ||| NNP
) ||| S:673 E:674 ||| -RRB-
,  ||| S:674 E:676 ||| ,
calcium  ||| S:676 E:684 ||| NN
( ||| S:684 E:685 ||| -LRB-
Ca ||| S:685 E:687 ||| NNP
) ||| S:687 E:688 ||| -RRB-
,  ||| S:688 E:690 ||| ,
phosphorus  ||| S:690 E:701 ||| NNS
( ||| S:701 E:702 ||| -LRB-
P ||| S:702 E:703 ||| NN
)  ||| S:703 E:705 ||| -RRB-
and  ||| S:705 E:709 ||| CC
magnesium  ||| S:709 E:719 ||| NNS
( ||| S:719 E:720 ||| -LRB-
Mg ||| S:720 E:722 ||| NNP
)  ||| S:722 E:724 ||| -RRB-
were  ||| S:724 E:729 ||| VBD
calculated  ||| S:729 E:740 ||| VBN
using  ||| S:740 E:746 ||| VBG
the  ||| S:746 E:750 ||| DT
manufacturer  ||| S:750 E:763 ||| NN
or  ||| S:763 E:766 ||| CC
NRC  ||| S:766 E:770 ||| NNP
values ||| S:770 E:776 ||| NNS
.  ||| S:776 E:778 ||| .
Blood  ||| S:778 E:784 ||| NN
samples ||| S:784 E:791 ||| NNS
,  ||| S:791 E:793 ||| ,
bodyweight  ||| S:793 E:804 ||| NN
and  ||| S:804 E:808 ||| CC
body  ||| S:808 E:813 ||| NN
condition  ||| S:813 E:823 ||| NN
score  ||| S:823 E:829 ||| NN
of  ||| S:829 E:832 ||| IN
horses  ||| S:832 E:839 ||| NNS
were  ||| S:839 E:844 ||| VBD
taken  ||| S:844 E:850 ||| VBN
precompetition ||| S:850 E:864 ||| NN
,  ||| S:864 E:866 ||| ,
30  ||| S:866 E:869 ||| CD
min  ||| S:869 E:873 ||| NNS
and  ||| S:873 E:877 ||| CC
18-24  ||| S:877 E:883 ||| CD
h  ||| S:883 E:885 ||| NN
after  ||| S:885 E:891 ||| IN
cross-country ||| S:891 E:904 ||| NNP
,  ||| S:904 E:906 ||| ,
but  ||| S:906 E:910 ||| CC
before  ||| S:910 E:917 ||| IN
stadium  ||| S:917 E:925 ||| NN
jumping ||| S:925 E:932 ||| NN
.  ||| S:932 E:934 ||| .
Data  ||| S:934 E:939 ||| NNP
were  ||| S:939 E:944 ||| VBD
analysed  ||| S:944 E:953 ||| VBN
using  ||| S:953 E:959 ||| VBG
a  ||| S:959 E:961 ||| DT
mixed  ||| S:961 E:967 ||| JJ
model  ||| S:967 E:973 ||| NN
ANOVA  ||| S:973 E:979 ||| NN
with  ||| S:979 E:984 ||| IN
repeated  ||| S:984 E:993 ||| JJ
measures  ||| S:993 E:1002 ||| NNS
and  ||| S:1002 E:1006 ||| CC
Pearson ||| S:1006 E:1013 ||| NNP
's  ||| S:1013 E:1016 ||| POS
product  ||| S:1016 E:1024 ||| NN
moment  ||| S:1024 E:1031 ||| NN
correlation ||| S:1031 E:1042 ||| NN
.  ||| S:1042 E:1044 ||| .
Estimated  ||| S:1044 E:1054 ||| JJ
daily  ||| S:1054 E:1060 ||| JJ
intakes  ||| S:1060 E:1068 ||| NN
of  ||| S:1068 E:1071 ||| IN
vitamin  ||| S:1071 E:1079 ||| JJ
E ||| S:1079 E:1080 ||| NN
,  ||| S:1080 E:1082 ||| ,
K ||| S:1082 E:1083 ||| NNP
,  ||| S:1083 E:1085 ||| ,
Ca ||| S:1085 E:1087 ||| NNP
,  ||| S:1087 E:1089 ||| ,
P  ||| S:1089 E:1091 ||| NN
and  ||| S:1091 E:1095 ||| CC
Mg  ||| S:1095 E:1098 ||| NNP
for  ||| S:1098 E:1102 ||| IN
horses  ||| S:1102 E:1109 ||| NNS
were  ||| S:1109 E:1114 ||| VBD
higher  ||| S:1114 E:1121 ||| JJR
than  ||| S:1121 E:1126 ||| IN
daily  ||| S:1126 E:1132 ||| JJ
recommended  ||| S:1132 E:1144 ||| JJ
levels  ||| S:1144 E:1151 ||| NNS
( ||| S:1151 E:1152 ||| -LRB-
P  ||| S:1152 E:1154 ||| NNP
< ||| S:1154 E:1156 ||| SYM
0.05 ||| S:1156 E:1160 ||| CD
) ||| S:1160 E:1161 ||| -RRB-
.  ||| S:1161 E:1163 ||| .
In  ||| S:1163 E:1166 ||| IN
response  ||| S:1166 E:1175 ||| NN
to  ||| S:1175 E:1178 ||| TO
competition ||| S:1178 E:1189 ||| NN
,  ||| S:1189 E:1191 ||| ,
tumour  ||| S:1191 E:1198 ||| FW
necrosis  ||| S:1198 E:1207 ||| FW
factor-α  ||| S:1207 E:1216 ||| FW
( ||| S:1216 E:1217 ||| -LRB-
TNFα ||| S:1217 E:1221 ||| NNP
;  ||| S:1221 E:1223 ||| :
P  ||| S:1223 E:1225 ||| NN
=  ||| S:1225 E:1227 ||| SYM
0.0002 ||| S:1227 E:1233 ||| CD
) ||| S:1233 E:1234 ||| -RRB-
,  ||| S:1234 E:1236 ||| ,
nitric  ||| S:1236 E:1243 ||| JJ
oxide  ||| S:1243 E:1249 ||| NN
( ||| S:1249 E:1250 ||| -LRB-
NO ||| S:1250 E:1252 ||| UH
;  ||| S:1252 E:1254 ||| :
P  ||| S:1254 E:1256 ||| NN
=  ||| S:1256 E:1258 ||| SYM
0.013 ||| S:1258 E:1263 ||| CD
)  ||| S:1263 E:1265 ||| -RRB-
and  ||| S:1265 E:1269 ||| CC
β-carotene  ||| S:1269 E:1280 ||| NNP
( ||| S:1280 E:1281 ||| -LRB-
BC ||| S:1281 E:1283 ||| NNP
;  ||| S:1283 E:1285 ||| :
P  ||| S:1285 E:1287 ||| NNP
< ||| S:1287 E:1289 ||| SYM
0.0001 ||| S:1289 E:1295 ||| NNP
)  ||| S:1295 E:1297 ||| -RRB-
decreased ||| S:1297 E:1306 ||| VBD
,  ||| S:1306 E:1308 ||| ,
creatine  ||| S:1308 E:1317 ||| FW
kinase  ||| S:1317 E:1324 ||| FW
( ||| S:1324 E:1325 ||| -LRB-
P  ||| S:1325 E:1327 ||| NNP
< ||| S:1327 E:1329 ||| SYM
0.0001 ||| S:1329 E:1335 ||| NNP
)  ||| S:1335 E:1337 ||| -RRB-
and  ||| S:1337 E:1341 ||| CC
aspartate  ||| S:1341 E:1351 ||| JJ
aminotransferase  ||| S:1351 E:1368 ||| NNS
( ||| S:1368 E:1369 ||| -LRB-
P  ||| S:1369 E:1371 ||| NN
=  ||| S:1371 E:1373 ||| SYM
0.001 ||| S:1373 E:1378 ||| CD
)  ||| S:1378 E:1380 ||| -RRB-
increased ||| S:1380 E:1389 ||| VBD
,  ||| S:1389 E:1391 ||| ,
and  ||| S:1391 E:1395 ||| CC
α-tocopherol  ||| S:1395 E:1408 ||| JJ
and  ||| S:1408 E:1412 ||| CC
retinol  ||| S:1412 E:1420 ||| NNS
did  ||| S:1420 E:1424 ||| VBD
not  ||| S:1424 E:1428 ||| RB
change ||| S:1428 E:1434 ||| VB
.  ||| S:1434 E:1436 ||| .
Intake  ||| S:1436 E:1443 ||| NNP
of  ||| S:1443 E:1446 ||| IN
vitamin  ||| S:1446 E:1454 ||| JJ
E ||| S:1454 E:1455 ||| NN
,  ||| S:1455 E:1457 ||| ,
K ||| S:1457 E:1458 ||| NNP
,  ||| S:1458 E:1460 ||| ,
Ca ||| S:1460 E:1462 ||| NNP
,  ||| S:1462 E:1464 ||| ,
P  ||| S:1464 E:1466 ||| NN
and  ||| S:1466 E:1470 ||| CC
bodyweight  ||| S:1470 E:1481 ||| NNS
were  ||| S:1481 E:1486 ||| VBD
negatively  ||| S:1486 E:1497 ||| RB
correlated  ||| S:1497 E:1508 ||| VBN
with  ||| S:1508 E:1513 ||| IN
TNFα  ||| S:1513 E:1518 ||| NNP
( ||| S:1518 E:1519 ||| -LRB-
P  ||| S:1519 E:1521 ||| NNP
< ||| S:1521 E:1523 ||| SYM
0.05 ||| S:1523 E:1527 ||| CD
) ||| S:1527 E:1528 ||| -RRB-
.  ||| S:1528 E:1530 ||| .
Vitamin  ||| S:1530 E:1538 ||| NNP
E  ||| S:1538 E:1540 ||| NNP
and  ||| S:1540 E:1544 ||| CC
bodyweight  ||| S:1544 E:1555 ||| NNS
were  ||| S:1555 E:1560 ||| VBD
also  ||| S:1560 E:1565 ||| RB
negatively  ||| S:1565 E:1576 ||| RB
correlated  ||| S:1576 E:1587 ||| VBN
with  ||| S:1587 E:1592 ||| IN
NO  ||| S:1592 E:1595 ||| DT
( ||| S:1595 E:1596 ||| -LRB-
P  ||| S:1596 E:1598 ||| NNP
< ||| S:1598 E:1600 ||| SYM
0.05 ||| S:1600 E:1604 ||| CD
) ||| S:1604 E:1605 ||| -RRB-
.  ||| S:1605 E:1607 ||| .
Pasture  ||| S:1607 E:1615 ||| JJ
intake  ||| S:1615 E:1622 ||| NN
and  ||| S:1622 E:1626 ||| CC
BC  ||| S:1626 E:1629 ||| NNP
were  ||| S:1629 E:1634 ||| VBD
positively  ||| S:1634 E:1645 ||| RB
correlated  ||| S:1645 E:1656 ||| JJ
( ||| S:1656 E:1657 ||| -LRB-
P  ||| S:1657 E:1659 ||| NNP
< ||| S:1659 E:1661 ||| SYM
0.0001 ||| S:1661 E:1667 ||| NNP
) ||| S:1667 E:1668 ||| -RRB-
.  ||| S:1668 E:1670 ||| .
The  ||| S:1670 E:1674 ||| DT
decline  ||| S:1674 E:1682 ||| NN
in  ||| S:1682 E:1685 ||| IN
systemic  ||| S:1685 E:1694 ||| JJ
inflammatory  ||| S:1694 E:1707 ||| JJ
markers  ||| S:1707 E:1715 ||| NN
is  ||| S:1715 E:1718 ||| VBZ
probably  ||| S:1718 E:1727 ||| RB
due  ||| S:1727 E:1731 ||| JJ
to  ||| S:1731 E:1734 ||| TO
increased  ||| S:1734 E:1744 ||| JJ
utilisation  ||| S:1744 E:1756 ||| NN
or  ||| S:1756 E:1759 ||| CC
excretion  ||| S:1759 E:1769 ||| NNS
and  ||| S:1769 E:1773 ||| CC
decreased  ||| S:1773 E:1783 ||| JJ
production  ||| S:1783 E:1794 ||| NN
related  ||| S:1794 E:1802 ||| VBN
to  ||| S:1802 E:1805 ||| TO
the  ||| S:1805 E:1809 ||| DT
increased  ||| S:1809 E:1819 ||| JJ
oxidative  ||| S:1819 E:1829 ||| NNS
stress  ||| S:1829 E:1836 ||| VBP
experienced  ||| S:1836 E:1848 ||| VBN
by  ||| S:1848 E:1851 ||| IN
horses  ||| S:1851 E:1858 ||| NNS
during  ||| S:1858 E:1865 ||| IN
competition ||| S:1865 E:1876 ||| NN
.  ||| S:1876 E:1878 ||| .
High  ||| S:1878 E:1883 ||| JJ
bodyweights  ||| S:1883 E:1895 ||| NN
could  ||| S:1895 E:1901 ||| MD
also  ||| S:1901 E:1906 ||| RB
predispose  ||| S:1906 E:1917 ||| VB
horses  ||| S:1917 E:1924 ||| NNS
to  ||| S:1924 E:1927 ||| TO
a  ||| S:1927 E:1929 ||| DT
higher  ||| S:1929 E:1936 ||| JJR
level  ||| S:1936 E:1942 ||| NN
of  ||| S:1942 E:1945 ||| IN
inflammation  ||| S:1945 E:1958 ||| NN
during  ||| S:1958 E:1965 ||| IN
3-day  ||| S:1965 E:1971 ||| CD
event  ||| S:1971 E:1977 ||| NN
competition ||| S:1977 E:1988 ||| NN
.  ||| S:1988 E:1990 ||| .
